Furthermore, we identify RRM2 as a crucial downstream effector of Cyclin Y involved in the biological processes associated with Cyclin Y. These findings suggest that targeting Cyclin Y could serve as a promising approach for enhancing the efficacy of radiotherapy in lung cancer treatment. This evidence concerns the gene CCNY and lung cancer.